Public record
Dupixent: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Medicaid
Medicaid prescriptions for Dupixent by state
State Medicaid programmes paid for 764,560 Dupixent prescriptions in 2025, with $3.04B reimbursed before rebates. New York reported the most (87,918), followed by California (79,105) and North Carolina (43,063); 52 states and territories reported any.
| Measure | Value | Note |
|---|---|---|
| Prescriptions paid by Medicaid, 2025 | 764,560 | |
| Total reimbursed before rebates, 2025 | $3.04B | |
| States and territories reporting | 52 | with at least one count CMS did not suppress |
| New York | 87,918 prescriptions | $348.1M reimbursed |
| California | 79,105 prescriptions | $317.6M reimbursed |
| North Carolina | 43,063 prescriptions | $173.3M reimbursed |
| Pennsylvania | 33,360 prescriptions | $137.1M reimbursed |
| Florida | 32,328 prescriptions | $131.9M reimbursed |
How this was calculated
Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.
Dupixent only (brand-name dupilumab), fee-for-service and managed care, 2025
Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.
Pharmacy cost
Pharmacy acquisition cost (NADAC) for Dupixent
Retail pharmacies paid an average of $1777.65 per mL for DUPIXENT 200 MG/1.14 ML PEN as of 2026-11-11, compared with $1689.01 twelve months earlier (+5.2%). This is a pharmacy purchase cost, not a patient price.
| Measure | Value | Note |
|---|---|---|
| DUPIXENT 200 MG/1.14 ML PEN | $1777.65 per mL | 12 months earlier $1689.01 (+5.2%) |
| DUPIXENT 200 MG/1.14 ML SYRING | $1774.22 per mL | 12 months earlier $1688.61 (+5.1%) |
| DUPIXENT 300 MG/2 ML PEN | $1008.94 per mL | 12 months earlier $960.57 (+5.0%) |
| DUPIXENT 300 MG/2 ML SYRINGE | $1010.74 per mL | 12 months earlier $962.44 (+5.0%) |
How this was calculated
Matched NADAC product codes to the FDA NDC Directory, kept finished single-ingredient products, and listed the product descriptions with the most package codes. The earlier price is the same package code in the file one year before.
Dupixent (brand-name dupilumab) in the weekly NADAC file of 2026-11-11, compared with the file of 2025-11-12
NADAC is the average invoice price retail pharmacies pay, from a voluntary survey. It leaves out rebates, dispensing fees and markups, and it is not what a patient or insurer pays. Compounded products are not surveyed.
Articles on Dupixent
- Does Aetna Cover Dupixent? Coverage Rules, Prior Authorization, and Cost Breakdown
- Does Anthem Cover Dupixent? A Step-by-Step Insurance Guide
- Does Blue Cross Blue Shield of Arizona Cover Dupixent?
- Does Blue Cross Blue Shield of Texas Cover Dupixent?
- Does Blue Shield of California Cover Dupixent?
- Does CareFirst BlueCross BlueShield Cover Dupixent?